
IL-6 and the Acute-Phase Response: Mapping Inflammatory States with Single-Cell/Spatial Omics, Biomarker Readouts, Precision Immunology (Part 3 of 3)
Introduction
The first two articles in this series focused on two different scales of IL-6 biology: the hepatic signaling pathway that converts an inflammatory input into acute-phase protein production, and the transcriptional and epigenetic mechanisms that can modify IL-6-responsive gene regulation.
The final problem is more heterogeneous.
IL-6 can support host defense and tissue repair during a transient acute response, yet persistent or excessive signaling can contribute to chronic inflammatory, autoimmune, metabolic, and malignant disease processes. At the same time, IL-6 biology varies across cell types, receptor states, tissues, and disease contexts [Tanaka et al., 2014; Mantovani and Garlanda, 2023; Hirano, 2021].
That heterogeneity creates a translational challenge. Blocking a pathway, measuring a biomarker, or identifying a cell state does not by itself establish which biological process is dominant in a particular disease or whether a measurement has sufficient clinical validity to guide an intervention.
This article therefore moves from pathobiology and IL-6-targeted treatment to selective trans-signaling, single-cell and spatial profiling, candidate biomarkers, and the validation requirements that stand between molecular resolution and precision immunology.
From Protective Acute Responses to Chronic Pathobiology
Acute-phase biology supports defense and tissue repair
The acute-phase response is fundamentally a host-defense program. By increasing antimicrobial defense, supporting tissue repair, and contributing to the restoration of homeostasis, it provides a coordinated systemic response to infection and tissue injury. IL-6 participates in this process both by inducing hepatic acute-phase protein production and by regulating immune responses [Tanaka et al., 2014; Mantovani and Garlanda, 2023].
This physiological role is important because IL-6 should not be treated as intrinsically pathological. The biological consequences of IL-6 depend on timing, magnitude, cellular context, and disease state.
Persistent IL-6 signaling becomes disease dependent
When IL-6 production or signaling becomes dysregulated and sustained, its functional meaning can change.
Persistent or excessive IL-6 activity has been implicated in chronic inflammatory and autoimmune diseases. In disease-dependent settings, it has also been linked to metabolic abnormalities such as obesity-associated insulin resistance and to the formation or progression of malignant tumors [Tanaka et al., 2014; Kim et al., 2009; Hirano, 2021].
Even within these broad categories, the mechanisms are not identical.
In atherosclerotic lesions, IL-6 signaling can participate in vascular-wall inflammation and plaque formation or progression. In the tumor microenvironment, chronic IL-6 signaling can support a tumor-promoting environment and immune evasion. In a hepatocellular carcinoma model, IL-6-activated JAK1 was shown to phosphorylate PD-L1 at Tyr112, promoting PD-L1 glycosylation and protein stabilization [Reiss et al., 2017; Fisher et al., 2014; Chan et al., 2019].
These examples illustrate why “IL-6-driven disease” should not be interpreted as a single conserved pathogenic mechanism across tissues.
What IL-6-Targeted Therapy Establishes—and What Safety Constrains
Established IL-6 and IL-6R blockade
The clinical effectiveness of IL-6-pathway blockade demonstrates that IL-6 can function as a therapeutically relevant disease driver in defined inflammatory disorders.
The anti-IL-6 receptor antibody tocilizumab has demonstrated efficacy in diseases including rheumatoid arthritis and systemic juvenile idiopathic arthritis. In the United States, the anti-IL-6 antibody siltuximab is approved for multicentric Castleman disease in patients who are HIV-negative and HHV-8-negative. [DailyMed, 2024] By interrupting IL-6 signaling, these approaches suppress inflammatory responses and the production of acute-phase proteins such as CRP [Jones and Ding, 2010; Yao et al., 2014; Choy et al., 2020].
Tocilizumab has demonstrated efficacy in rheumatoid arthritis and giant-cell arteritis [Jones et al., 2010; Stone et al., 2017].
Suppression of CRP after IL-6 blockade is mechanistically expected because CRP lies downstream of hepatic IL-6 signaling. However, suppression of an acute-phase biomarker should not be equated automatically with complete resolution of the underlying disease process.
Infection risk and safety monitoring depend on patient context
Therapeutic efficacy is only one side of cytokine intervention.
These data support the general clinical principle that treatment selection and safety monitoring should take both disease activity and background infection risk into account, including factors such as age, disease duration, respiratory disease, and concomitant corticosteroid use [Schiff et al., 2011; Koike et al., 2014].
The mechanistic significance is broader than any one treatment decision: IL-6 participates in host-defense biology, and pathway inhibition therefore has consequences that cannot be evaluated solely by measuring suppression of inflammatory biomarkers.
This is also why treatment efficacy does not erase disease-specific complexity. IL-6/gp130–JAK–STAT3 signaling contributes to inflammatory and autoimmune disease, while related signaling in the tumor microenvironment has been investigated as a potential target in cancer biology and therapeutic resistance [Kishimoto and Kang, 2022; Taniguchi and Karin, 2014; Kumari et al., 2016].
A continuing research challenge is to determine how strongly particular disease states and patient subgroups depend on IL-6 signaling, so that future IL-6-targeted strategies can be refined without assuming uniform pathway dependence [Hirano, 2021; Choy et al., 2020].
Selective Trans-Signaling Blockade Tests a More Refined Therapeutic Hypothesis
The rationale for sgp130Fc / olamkicept
One attempt to refine IL-6 targeting is to distinguish classic signaling through membrane-bound IL-6R from trans-signaling mediated by soluble IL-6R.
Olamkicept (sgp130Fc) remains an investigational agent that selectively inhibits IL-6 trans-signaling. [ClinicalTrials.gov, NCT06515834] The therapeutic rationale has been to suppress inflammatory effects associated with trans-signaling while preserving functions associated with classic signaling, including aspects of the antimicrobial acute-phase response [Rose-John, 2012; Wolf et al., 2014].
Olamkicept has been evaluated in a phase 2a study in active inflammatory bowel disease, providing clinical evidence that selective trans-signaling blockade can be investigated as an alternative to global IL-6-pathway inhibition [Schreiber et al., 2021].
Evidence across experimental and clinical contexts
Experimental studies add further support for the biological separability of the two signaling modes.
Selective blockade of IL-6 trans-signaling with sgp130Fc improved outcomes in a murine polymicrobial sepsis model, and pharmacological trans-signaling inhibition has also been examined in impaired fracture healing after severe trauma [Barkhausen et al., 2011; Kaiser et al., 2018].
These studies do not establish a universal therapeutic rule. They demonstrate that selective manipulation of signaling mode can produce effects distinct from broad IL-6 inhibition in specific models.
Why classic and trans-signaling do not map cleanly onto “physiological” and “pathological”
A simple binary interpretation would be attractive: classic signaling preserves beneficial functions, whereas trans-signaling drives pathology.
The available evidence does not support such a complete separation.
IL-6 trans-signaling can contribute to liver regeneration after partial hepatectomy, indicating that trans-signaling itself can participate in a regenerative process [Modares et al., 2019]. Cellular responses to classic and trans-signaling also depend on factors such as the relative expression of IL-6 receptor α (IL-6Rα) and gp130 [Reeh et al., 2019].
Thus, selective trans-signaling inhibition represents a mechanistically refined hypothesis, not proof that one signaling mode is universally physiological and the other universally pathological [Rose-John, 2012; Schreiber et al., 2021; Modares et al., 2019].
Single-Cell and Spatial Profiling Resolve Inflammatory Heterogeneity
Cell states, receptor expression, and inferred intercellular signaling
Bulk tissue measurements compress biological heterogeneity into an average signal. Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics provide a different type of information.
By integrating these approaches, it is possible to distinguish cell populations such as hepatocytes, Kupffer cells, and hepatic stellate cells; map the distributions of IL6, IL6R, and related gene expression; and relate ligand–receptor-based predictions of intercellular signaling to spatial position within tissue [Saviano et al., 2020; Zou et al., 2023].
This increases the resolution at which IL-6 biology can be studied. It becomes possible to ask not only whether an IL-6-associated signal is present in a tissue, but which cell populations express the relevant components and where those populations are located.
Ligand–receptor analysis, however, produces an inference of possible intercellular communication. It should not be interpreted automatically as demonstration of causal signaling between two cell populations.
Spatial context reveals what bulk measurements cannot
Single-cell and spatial methods can resolve molecular profiles of distinct subpopulations, potential cellular cross-talk during inflammatory responses, and inflammatory dynamics within local microenvironments that are not visible in homogenized tissue analyses [MacParland et al., 2018; Saviano et al., 2020; Zou et al., 2023].
This is particularly important for a pleiotropic cytokine such as IL-6. The same ligand can produce different responses depending on receptor availability, cell identity, intracellular state, and the signaling mode that is accessible to the cell.
Single-cell transcriptomic studies have identified IL-6-associated cellular subsets in disease contexts, while functional and dynamic modeling has shown that the relative expression of IL-6Rα and gp130 can influence responsiveness to classic and trans-signaling [Paldor et al., 2022; Reeh et al., 2019].
IL-6 and soluble IL-6R can also contribute to temporal changes in leukocyte recruitment during acute inflammation, illustrating that the relevant cellular network can change over time rather than remaining static [Hurst et al., 2001].
Recent single-cell studies continue to identify disease-associated immune-cell states linked to inflammatory mediators, but an integrated mechanism that explains persistence and resolution of inflammation across tissues and diseases remains under investigation [Xu et al., 2025].
Biomarker Readouts: From Association to Stratification
Moving beyond CRP and SAA
CRP and SAA have long been used as representative systemic inflammatory biomarkers. Their usefulness, however, does not make them specific readouts of IL-6 pathway state.
For that reason, research has increasingly examined molecules more closely related to IL-6 signaling itself. Proposed candidates include soluble IL-6 receptor (sIL-6R), soluble gp130 (sgp130), and other components associated with regulation of IL-6 signaling [Black et al., 2004; Sack, 2018; Zhou et al., 2020; Ziegler et al., 2022].
The goal is greater biological resolution: not simply to measure that inflammation is present, but to determine whether a specific cytokine-signaling configuration is associated with a disease state.
Phosphorylated STAT3, soluble receptors, and epigenetic markers remain candidate signals
Disease-specific studies have extended this concept to phosphorylated STAT3 (pSTAT3) in peripheral immune cells, circulating IL-6-associated molecules including sIL-6R and sgp130, and inflammation-associated epigenetic features such as DNA methylation or noncoding RNAs [Kuuliala et al., 2015; Lokau et al., 2025; Triantaphyllopoulos et al., 2025].
These variables have been evaluated in relation to disease activity, biological stratification, or treatment response.
What has not been established is a generic, clinically validated biomarker panel that integrates these different layers across diseases.
This distinction matters. A molecule can be biologically associated with IL-6 activity without being sufficiently validated to support clinical classification, prediction, or treatment selection.
Multilayer biomarker models and precision stratification
The longer-term ambition is to combine multiple biological dimensions rather than depend on a single marker.
In immune-mediated inflammatory diseases and rheumatoid arthritis, research is increasingly examining whether pathogenic drivers, genetic background, immune context, and signature cytokine profiles including IL-6 can be integrated to stratify treatment response and prognosis and support precision-medicine approaches [Schett et al., 2021; Meehan et al., 2021; Sharma et al., 2024].
This direction is scientifically plausible because heterogeneous diseases are unlikely to be captured completely by one systemic marker. Yet increasing the number of measured variables does not by itself establish a clinically useful model. Analytical performance, biological reproducibility, prospective validation, and evidence that the model improves clinical decisions all remain separate requirements.

This translational research roadmap contrasts protective acute IL-6 responses with persistent or dysregulated signaling and distinguishes established IL-6/IL-6R blockade from investigational selective trans-signaling inhibition with olamkicept (sgp130Fc). Single-cell and spatial profiling can identify cell, receptor, and tissue states that may inform candidate biomarker discovery, functional validation, biological stratification, and prospective studies. Candidate biomarkers are not equivalent to validated clinical tools, predicted interactions do not establish causality, and this research roadmap is not an individual treatment algorithm. Conceptual schematic; not clinical guidance.
Abbreviations: CRP, C-reactive protein; SAA, serum amyloid A; sIL-6R, soluble IL-6 receptor; sgp130, soluble gp130; pSTAT3, phosphorylated STAT3; sgp130Fc, olamkicept; scRNA-seq, single-cell RNA sequencing.
Toward Precision Immunology: What Still Requires Validation
Connecting single-cell, spatial, network, and machine-learning approaches
The next stage of IL-6 research is increasingly integrative.
Dynamic analysis of IL-6 responsiveness—including variation in IL-6Rα/gp130 expression and receptor localization—can potentially be connected with single-cell and spatial transcriptomics, network biology, and machine learning to describe IL-6-associated cell states and tissue niches at higher resolution [Reeh et al., 2019; Schmidt-Arras and Rose-John, 2021; Thomas et al., 2021; Wang et al., 2021; Li et al., 2025].
Such integration could help prioritize disease-associated regulatory candidates, generate drug-discovery hypotheses, or develop models of treatment response.
At present, these applications remain research-stage approaches that require disease-specific functional validation. A computationally prioritized target is not yet a validated therapeutic target, and a predictive model is not automatically a clinically actionable decision tool.
Patient stratification and pharmacodynamic modeling
A related goal is to integrate molecular and clinical profiles with pharmacodynamic modeling.
In principle, this could improve patient stratification and increase the precision with which IL-6-targeted interventions are studied or designed. However, implementation requires validated biomarkers, disease-specific assessment of efficacy and safety, and clinical evidence that stratification results can be translated into beneficial interventions [Delhalle et al., 2018; Choy et al., 2020; Rossi et al., 2022].
The distinction between research design and clinical utility is essential. Molecular stratification can define biologically interesting subgroups before it becomes suitable for guiding care.
Functional validation before target or treatment claims
Single-cell and spatial analyses are well suited to identifying disease-associated cell states and candidate regulatory molecules. CRISPR–dCas9-based epigenome editing and related experimental tools provide possible ways to test the functional relevance of selected candidates.
Combining these approaches could support the discovery of disease-dependent therapeutic targets or stratification markers [Choy et al., 2020; Paldor et al., 2022; Zou et al., 2023; Stover et al., 2019; Delhalle et al., 2018].
But this integrated strategy remains preclinical and methodological. Identification of a candidate in an omics dataset is only the beginning of the evidence chain. Functional perturbation, replication, disease-specific validation, safety assessment, and ultimately clinical testing remain necessary before a candidate can be treated as a therapeutic or clinical-stratification tool.
IL-6 biology remains both protective and pathological
The central biological tension that began this article therefore remains unresolved by technological sophistication.
Transient IL-6 signaling during infection or tissue injury can support acute-phase protein production and immune defense. Excessive or persistent signaling can contribute to chronic inflammation, autoimmunity, and some cancers [Hirano, 2021; Tanaka et al., 2014].
Higher-resolution measurement does not eliminate this duality. Instead, it makes the contextual question more precise: which cells, signaling modes, molecular states, and disease mechanisms are responsible for IL-6 dependence in a particular biological system?
Prospective validation and long-term outcomes are the final bottleneck
The path from mechanistic understanding to precision immunology therefore requires more than increasingly detailed molecular maps.
Validated biomarkers must be integrated with patient stratification and treatment-response prediction, while tissue injury and remodeling must also be considered. For these approaches to become clinically meaningful, disease-specific prospective validation and assessment of long-term outcomes are required [Mantovani and Garlanda, 2023; Lamb et al., 2022].
Conclusion
IL-6 biology spans several levels of organization.
At the molecular level, IL-6 engages receptor systems that activate gp130–JAK–STAT3 signaling. At the physiological level, transient signaling supports the hepatic acute-phase response and host defense. In chronic disease, persistent pathway activation can become pathogenic. Therapeutically, established IL-6 or IL-6R blockade demonstrates the importance of the pathway in specific disorders but also exposes safety constraints inherent to manipulating an immune cytokine.
Selective trans-signaling inhibition attempts to refine that intervention logic, yet current evidence does not support a simple physiological-versus-pathological division between classic and trans-signaling.
Single-cell and spatial technologies now allow IL-6-associated cell states, receptor configurations, and tissue niches to be resolved with increasing precision. Candidate biomarkers and multilayer models extend that resolution toward stratification. Network biology, machine learning, pharmacodynamic modeling, and functional perturbation may eventually help connect these measurements to more precise therapeutic hypotheses.
The decisive step, however, remains validation.
Association is not mechanism. Mechanism is not prediction. Prediction is not clinical utility. And suppression of an IL-6-dependent biomarker is not equivalent to resolution of the entire disease process.
The next phase of precision immunology will therefore depend not only on measuring inflammatory states at higher resolution, but on demonstrating—prospectively and over clinically relevant time scales—which measurements and mechanisms actually improve outcomes.
This article provides general scientific and medical information. It does not interpret individual laboratory results or provide guidance on diagnosis, drug selection, dosing, treatment initiation, modification, or discontinuation.
Medical Disclaimer
This article provides general scientific and medical information. It is not intended to interpret individual laboratory results or to support diagnosis, treatment selection, dosing, treatment modification, or treatment discontinuation.
Production Note
Figures were created with AI assistance and reviewed by the author for scientific accuracy and clarity.
Related Articles
Work With Rin Kamo
For science writing, biomedical content development, literature research, or scientific editing inquiries, see “Work With Rin Kamo: Science Writing & Biomedical Content Support.”
References
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295. doi:10.1101/cshperspect.a016295. PMID:25190079; PMCID:PMC4176007.
Mantovani A, Garlanda C. Humoral innate immunity and acute-phase proteins. N Engl J Med. 2023;388(5):439–452. doi:10.1056/NEJMra2206346. PMID:36724330; PMCID:PMC9912245.
Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127–148. doi:10.1093/intimm/dxaa078. PMID:33337480; PMCID:PMC7799025.
Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm. 2009;80:613–633. doi:10.1016/S0083-6729(08)00621-3. PMID:19251052.
Reiss AB, Siegart NM, De Leon J. Interleukin-6 in atherosclerosis: atherogenic or atheroprotective? Clin Lipidol. 2017;12(1):14–23. doi:10.1080/17584299.2017.1319787.
Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38–47. doi:10.1016/j.smim.2014.01.008. PMID:24602448; PMCID:PMC3970580.
Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest. 2019;129(8):3324–3338. doi:10.1172/JCI126022. PMID:31305264; PMCID:PMC6668668.
DailyMed. SYLVANT (siltuximab) for injection, for intravenous use: U.S. prescribing information. U.S. National Library of Medicine. Label updated August 27, 2024; revised June 2024. Accessed August 9, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8d663642-f52e-49c0-a023-2da083fdfc0b.
Jones G, Ding C. Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2010;3:81–89. doi:10.4137/CMAMD.S4864. PMID:21234291; PMCID:PMC3018893.
Yao X, Huang J, Zhong H, Shen N, Faggioni R, Fung M, Yao Y. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141(2):125–139. doi:10.1016/j.pharmthera.2013.09.004. PMID:24076269.
Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345. doi:10.1038/s41584-020-0419-z. PMID:32327746; PMCID:PMC7178926.
Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96. doi:10.1136/ard.2008.105197. PMID:19297346.
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849. PMID:28745999.
Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi:10.1186/ar3455. PMID:21884601; PMCID:PMC3308069.
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15–23. doi:10.3899/jrheum.130466. PMID:24187110.
Kishimoto T, Kang S. IL-6 revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol. 2022;40:323–348. doi:10.1146/annurev-immunol-101220-023458. PMID:35113729.
Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26(1):54–74. doi:10.1016/j.smim.2014.01.001. PMID:24552665.
Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–11572. doi:10.1007/s13277-016-5098-7. PMID:27260630.
ClinicalTrials.gov. NCT06515834. Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept at Higher Doses. U.S. National Library of Medicine. Accessed August 9, 2026. https://clinicaltrials.gov/study/NCT06515834.
Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–1247. doi:10.7150/ijbs.4989. PMID:23136552; PMCID:PMC3491447.
Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70(1):11–20. doi:10.1016/j.cyto.2014.05.024. PMID:24986424.
Schreiber S, Aden K, Bernardes JP, Conrad C, Tran F, Höper H, et al. Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease. Gastroenterology. 2021;160(7):2354–2366.e11. doi:10.1053/j.gastro.2021.02.062. PMID:33667488.
Barkhausen T, Tschernig T, Rosenstiel P, van Griensven M, Vonberg RP, Dorsch M, et al. Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med. 2011;39(6):1407–1413. doi:10.1097/CCM.0b013e318211ff56. PMID:21336117.
Kaiser K, Prystaz K, Vikman A, Haffner-Luntzer M, Bergdolt S, Strauss G, et al. Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma. Naunyn Schmiedebergs Arch Pharmacol. 2018;391(5):523–536. doi:10.1007/s00210-018-1483-7. PMID:29497762; PMCID:PMC5889421.
Modares NF, Polz R, Haghighi F, Lamertz L, Behnke K, Zhuang Y, et al. IL-6 trans-signaling controls liver regeneration after partial hepatectomy. Hepatology. 2019;70(6):2075–2091. doi:10.1002/hep.30774. PMID:31100194.
Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17(1):46. doi:10.1186/s12964-019-0356-0. PMID:31101051; PMCID:PMC6525395.
Saviano A, Henderson NC, Baumert TF. Single-cell genomics and spatial transcriptomics: discovery of novel cell states and cellular interactions in liver physiology and disease biology. J Hepatol. 2020;73(5):1219–1230. doi:10.1016/j.jhep.2020.06.004. PMID:32534107; PMCID:PMC7116221.
Zou J, Li J, Zhong X, Tang D, Fan X, Chen R. Liver in infections: a single-cell and spatial transcriptomics perspective. J Biomed Sci. 2023;30(1):53. doi:10.1186/s12929-023-00945-z. PMID:37430371; PMCID:PMC10332047.
MacParland SA, Liu JC, Ma XZ, Innes BT, Bartczak AM, Gage BK, et al. Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations. Nat Commun. 2018;9(1):4383. doi:10.1038/s41467-018-06318-7. PMID:30348985; PMCID:PMC6197289.
Paldor M, Levkovitch-Siany O, Eidelshtein D, Adar R, Enk CD, Marmary Y, et al. Single-cell transcriptomics reveals a senescence-associated IL-6/CCR6 axis driving radiodermatitis. EMBO Mol Med. 2022;14(8):e15653. doi:10.15252/emmm.202115653. PMID:35785521; PMCID:PMC9358397.
Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001;14(6):705–714. doi:10.1016/S1074-7613(01)00151-0. PMID:11420041.
Xu X, Chen J, Yu X, Li Z, Chen J, Fang D, et al. Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure. Gut. 2025 Oct 6:gutjnl-2025-335998. doi:10.1136/gutjnl-2025-335998. PMID:41052916.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279(47):48487–48490. doi:10.1074/jbc.R400025200. PMID:15337754.
Sack GH Jr. Serum amyloid A—a review. Mol Med. 2018;24(1):46. doi:10.1186/s10020-018-0047-0. PMID:30165816.
Zhou M, Dai W, Cui Y, Liu H, Li Y. Associations between the IL-6-neutralizing sIL-6R-sgp130 buffer system and coronary artery disease in postmenopausal women. Ann Transl Med. 2020;8(6):379. doi:10.21037/atm.2020.02.27. PMID:32355823.
Ziegler L, Lundström A, Havervall S, Thålin C, Gigante B. IL-6 signalling biomarkers in hospitalised patients with moderate to severe SARS-CoV-2 infection in a single centre study in Sweden. Cytokine. 2022;159:156020. doi:10.1016/j.cyto.2022.156020. PMID:36057230; PMCID:PMC9420722.
Kuuliala K, Kuuliala A, Koivuniemi R, Oksanen S, Hämäläinen M, Moilanen E, et al. Constitutive STAT3 phosphorylation in circulating CD4+ T lymphocytes associates with disease activity and treatment response in recent-onset rheumatoid arthritis. PLoS One. 2015;10(9):e0137385. doi:10.1371/journal.pone.0137385. PMID:26353115; PMCID:PMC4564221.
Lokau J, Garbers Y, Vicente MM, Dittrich A, Meltendorf S, Lingel H, et al. Long-term increase in soluble interleukin-6 receptor levels in convalescents after mild COVID-19 infection. Front Immunol. 2025;15:1488745. doi:10.3389/fimmu.2024.1488745. PMID:39835136; PMCID:PMC11743636.
Triantaphyllopoulos KA, Ragia ND, Panagiotopoulou MCE, Sourlingas TG. Integrating inflammatory and epigenetic signatures in IBD-associated colorectal carcinogenesis: models, mechanisms, and clinical implications. Int J Mol Sci. 2025;26(19):9498. doi:10.3390/ijms26199498. PMID:41096771; PMCID:PMC12524939.
Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. 2021;385(7):628–639. doi:10.1056/NEJMra1909094. PMID:34379924.
Meehan RT, Amigues IA, Knight V. Precision medicine for rheumatoid arthritis: the right drug for the right patient—companion diagnostics. Diagnostics (Basel). 2021;11(8):1362. doi:10.3390/diagnostics11081362. PMID:34441297.
Sharma SD, Bluett J. Towards personalized medicine in rheumatoid arthritis. Open Access Rheumatol. 2024;16:89–114. doi:10.2147/OARRR.S372610. PMID:38779469.
Schmidt-Arras D, Rose-John S. Endosomes as signaling platforms for IL-6 family cytokine receptors. Front Cell Dev Biol. 2021;9:688314. doi:10.3389/fcell.2021.688314. PMID:34141712; PMCID:PMC8204807.
Thomas JP, Modos D, Korcsmaros T, Brooks-Warburton J. Network biology approaches to achieve precision medicine in inflammatory bowel disease. Front Genet. 2021;12:760501. doi:10.3389/fgene.2021.760501. PMID:34745229; PMCID:PMC8566351.
Wang H, Pujos-Guillot E, Comte B, de Miranda JL, Spiwok V, Chorbev I, et al. Deep learning in systems medicine. Brief Bioinform. 2021;22(2):1543–1559. doi:10.1093/bib/bbaa237. PMID:33197934; PMCID:PMC8382976.
Li Y, Qiu H, Zhao Z, Qi F, Cai P. Single-cell technologies and spatial transcriptomics: decoding immune low-response states in endometrial cancer. Front Immunol. 2025;16:1636483. doi:10.3389/fimmu.2025.1636483. PMID:40672944; PMCID:PMC12263668.
Delhalle S, Bode SFN, Balling R, Ollert M, HeFeng FQ. A roadmap towards personalized immunology. NPJ Syst Biol Appl. 2018;4:9. doi:10.1038/s41540-017-0045-9. PMID:29423275; PMCID:PMC5802799.
Rossi JF, Chiang HC, Lu ZY, Levon K, van Rhee F, Kanhai K, Fajgenbaum DC, Klein B. Optimisation of anti-interleukin-6 therapy: precision medicine through mathematical modelling. Front Immunol. 2022;13:919489. doi:10.3389/fimmu.2022.919489. PMID:35928820.
Stover JD, Farhang N, Lawrence B, Bowles RD. Multiplex epigenome editing of dorsal root ganglion neuron receptors abolishes redundant interleukin 6, tumor necrosis factor alpha, and interleukin 1β signaling by the degenerative intervertebral disc. Hum Gene Ther. 2019;30(9):1147–1160. doi:10.1089/hum.2019.032. PMID:31056946.
Lamb CA, Saifuddin A, Powell N, Rieder F. The future of precision medicine to predict outcomes and control tissue remodeling in inflammatory bowel disease. Gastroenterology. 2022;162(5):1525–1542. doi:10.1053/j.gastro.2021.09.077. PMID:34995532; PMCID:PMC8983496.